Dilger James P, Vidal Ana Maria, Liu Man, Mettewie Claire, Suzuki Takahiro, Pham Anh, Demazumder Deeptankar
Department of Anesthesiology, Stony Brook University, NY 11794-8480, USA, and Department of Anesthesiology, Surugadai Nihon University Hospital, Kanda, Tokyo, Japan.
Anesthesiology. 2007 Jun;106(6):1186-95. doi: 10.1097/01.anes.0000267602.94516.7f.
Binding sites for agonists and competitive antagonists (nondepolarizing neuromuscular blocking agents) are located at the alpha-delta and alpha-epsilon subunit interfaces of adult nicotinic acetylcholine receptors. Most information about the amino acids that participate in antagonist binding comes from binding studies with (+)-tubocurarine and metocurine. These bind selectively to the alpha-epsilon interface but are differentially sensitive to mutations. To test the generality of this observation, the authors measured current inhibition by five competitive antagonists on wild-type and mutant acetylcholine receptors.
HEK293 cells were transfected with wild-type or mutant (alphaY198F, epsilonD59A, epsilonD59N, epsilonD173A, epsilonD173N, deltaD180K) mouse muscle acetylcholine receptor complementary DNA. Outside-out patches were excised and perfused with acetylcholine in the absence and presence of antagonist. Concentration-response curves were constructed to determine antagonist IC50. An antagonist-removal protocol was used to determine dissociation and association rates.
Effects of mutations were antagonist specific. alphaY198F decreased the IC50 of (+)-tubocurarine 10-fold, increased the IC50 of vecuronium 5-fold, and had smaller effects on other antagonists. (+)-Tubocurarine was the most sensitive antagonist to epsilonD173 mutations. epsilonD59 mutations had large effects on metocurine and cisatracurium. deltaD180K decreased inhibition by pancuronium, vecuronium, and cisatracurium. Inhibition by these antagonists was increased for receptors containing two delta subunits but no epsilon subunit. Differences in IC50 arose from differences in both dissociation and association rates.
Competitive antagonists exhibited different patterns of sensitivity to mutations. Except for pancuronium, the antagonists were sensitive to mutations at the alpha-epsilon interface. Pancuronium, vecuronium, and cisatracurium were selective for the alpha-delta interface. This suggests the possibility of synergistic inhibition by pairs of antagonists.
激动剂和竞争性拮抗剂(非去极化神经肌肉阻滞剂)的结合位点位于成人烟碱型乙酰胆碱受体的α-δ和α-ε亚基界面。关于参与拮抗剂结合的氨基酸的大多数信息来自与(+)-筒箭毒碱和美库氯铵的结合研究。这些物质选择性地结合到α-ε界面,但对突变的敏感性不同。为了检验这一观察结果的普遍性,作者测量了五种竞争性拮抗剂对野生型和突变型乙酰胆碱受体的电流抑制作用。
用野生型或突变型(αY198F、εD59A、εD59N、εD173A、εD173N、δD180K)小鼠肌肉乙酰胆碱受体互补DNA转染HEK293细胞。切下外向型膜片并在不存在和存在拮抗剂的情况下用乙酰胆碱灌注。构建浓度-反应曲线以确定拮抗剂的半数抑制浓度(IC50)。使用拮抗剂去除方案来确定解离和结合速率。
突变的影响具有拮抗剂特异性。αY198F使(+)-筒箭毒碱的IC50降低10倍,使维库溴铵的IC50增加了5倍,对其他拮抗剂的影响较小。(+)-筒箭毒碱是对εD173突变最敏感的拮抗剂。εD59突变对美库氯铵和顺式阿曲库铵有很大影响。δD180K降低了泮库溴铵、维库溴铵和顺式阿曲库铵的抑制作用。对于含有两个δ亚基但没有ε亚基的受体,这些拮抗剂的抑制作用增强。IC50的差异源于解离和结合速率的差异。
竞争性拮抗剂对突变表现出不同的敏感性模式。除泮库溴铵外,拮抗剂对α-ε界面的突变敏感。泮库溴铵、维库溴铵和顺式阿曲库铵对α-δ界面具有选择性。这表明拮抗剂对可能存在协同抑制作用。